5-FU	5-fluoruracil
ACT	adoptive cell therapy
ADM	acinar-to-ductal metaplasia
apCAF	antigen presenting CAF
BiTE	bispecific T cell engager
BRCA	breast cancer susceptibility protein
CAF	cancer associated fibroblast
CAR	chimeric antigen receptor
CCL	Chemokine (C-C motif) ligand
CSF-1	colony-stimulating factor-1
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
CXCL	C-X-C motif binding chemokine
CXCR	C-X-C motif chemokine receptor
DC	dendritic cell
dMMR	deficient mismatch repair
EMT	epithelial to mesenchymal transition
FDA	Food and Drug Administration
FOLFIRINOX	5-fluoruracil, folinic acid, irinotecan, oxaliplatin
GM-CSF	granulocyte-macrophage colony-stimulating factor
iCAF	inflammatory CAF
ICI	immune checkpoint inhibitor
ICOSL	induced costimulatory ligand
IL	interleukin
IPMN	intraductal papillary mucinous neoplasm
M-CSF	macrophage colony-stimulating factor
MCN	mucinous cystic neoplasm
MDSC	myeloid-derived suppressor cell
MMP-9	matrix metalloproteinase-9
MUC16	Mucin-16
mRNA	messenger ribonucleic acid
MSI-H	high microsatellite instability
myCAF	myofibroblastic CAF
n.a.	not applicable
NK cell	natural killer cell
OS	overall survival
PanIN	pancreatic intraepithelial neoplasm
PARP	poly(ADP-ribose)-polymerase
PBMC	peripheral blood mononuclear cell
PD-1	programmed cell death protein 1
PD-L1	programmed cell death 1 ligand 1
PDAC	pancreatic ductal adenocarcinoma
PFS	progression-free survival
TAM	tumor-associated macrophage
TCR	T cell receptor
TGF-β	transforming growth factor β
TIL	tumor-infiltrating leucocyte
TNF-α	tumor necrosis factor α
Treg	regulatory T cell
α-SMA	α smooth muscle actin